Indication
Staphylococcus aureus
11 clinical trials
15 products
1 drug
Clinical trial
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy for the Treatment of Adults With Bacteremia Due to Staphylococcus AureusStatus: Recruiting, Estimated PCD: 2024-12-01
Product
AP-SA02Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention of Nosocomial PneumoniaStatus: Recruiting, Estimated PCD: 2023-10-01
Product
PlaceboProduct
SuvratoxumabProduct
AR-301Clinical trial
A Randomized Double-blind Placebo-controlled Multicenter Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-Associated Pneumonia (VAP) Caused by S. AureusStatus: Completed, Estimated PCD: 2022-10-28
Clinical trial
Comparing Single Versus Repeat Parent-to-Child Nasal Microbiome Transplant on Seeding, Engraftment, and Diversity of the Neonatal Nasal MicrobiomeStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Product
Nasal Microbiota TransplantClinical trial
Interleukin-4Ralpha Blockade by Dupilumab Decreases Staphylococcus Aureus Colonization and Increases Microbial Diversity in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)Status: Recruiting, Estimated PCD: 2024-06-30
Product
DupilumabClinical trial
Cluster-randomized Non-inferiority Trial Comparing Mupirocin vs Iodophor for Nasal Decolonization of ICU Patients to Assess Impact on S. Aureus Clinical Cultures and All-cause Bloodstream Infection During Routine Chlorhexidine BathingStatus: Completed, Estimated PCD: 2023-11-06
Product
Mupirocin + CHGProduct
Iodophor + CHGClinical trial
A Randomized Double-blind Placebo-controlled First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of a Recombinant Chimeric Bacteriophage Endolysin HY-133 With an Extended Phase to Evaluate Effects of the Nasal MicrobiomeStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Product
HY_133Drug
VarlilumabClinical trial
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant to Promote Colonization Resistance to Staphylococcus AureusStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Integrating Personal and Household Environmental Hygiene Measures to Prevent Methicillin-Resistant Staphylococcus Aureus InfectionStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
ChlorhexidineProduct
MupirocinClinical trial
A Randomized, Multi-Center Trial to Evaluate the Safety & Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy VolunteersStatus: Completed, Estimated PCD: 2011-03-01
Product
Monovalent rATProduct
rLukS-PVProduct
Bivalent rLukS-PV / rATClinical trial
Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military TraineesStatus: Completed, Estimated PCD: 2012-01-01
Product
Chlorhexidine gluconate